NUR 635 ADVANCED PHARMACOLOGY
OBJECTIVE ASSESSMENT - EXAM
NUR 635 FINAL EXAM 1 GCU 2026/2027 LATEST
VERSION WITH 130+ ACTUAL EXAM QUESTIONS AND
100% CORRECT ANSWERS GRADED A+ / NUR 635
ADVANCED PHARMACOLOGY ACTUAL FINAL EXAM
2026/2027 (BRAND NEW!!) 2026/2027
A+ Verified Edition: 2026/2027 Passing Score: 80%
Graduate-Level Advanced Pharmacology | Analysis & Evaluation
COVER PAGE - 1
,NUR 635 FINAL EXAM 1 GCU 2026/2027 | ADVANCED PHARMACOLOGY Page 2
SECTIONS COVERED
1. Section 1: Pharmacokinetics, Pharmacodynamics & Principles of Drug Action (22 questions)
2. Section 2: Autonomic Nervous System & Cardiovascular Pharmacology (22 questions)
3. Section 3: Central Nervous System Pharmacology (22 questions)
4. Section 4: Antimicrobial & Anti-Infective Pharmacotherapy (22 questions)
5. Section 5: Endocrine, Respiratory & Gastrointestinal Pharmacology (21 questions)
6. Section 6: Special Populations, Adverse Effects & Clinical Decision-Making (21 questions)
This examination assesses advanced knowledge of pharmacology principles, drug classes, therapeutic applications, adverse-effect
profiles, and clinical decision-making at the graduate level. Each question is worth 1 mark. Passing score: 80%.
Section 1: Pharmacokinetics, Pharmacodynamics & Principles of Drug Action
Question 1
A 68-year-old patient with chronic kidney disease stage 4 is prescribed a new renally cleared antibiotic. The nurse practitioner
reviews the pharmacokinetic profile and notes the drug has a high volume of distribution and is primarily eliminated unchanged in
urine. Which adjustment is most appropriate to maintain therapeutic levels while minimizing toxicity?
A. Increase the dose and extend the dosing interval
B. Maintain the standard dose and shorten the dosing interval
C. Reduce the dose and maintain the standard dosing interval
D. Reduce the dose and extend the dosing interval
Correct Answer: D
Rationale:
For renally cleared drugs with high Vd in CKD, both dose reduction and interval extension are often needed to account for reduced clearance
while respecting distribution. Option C alone may still lead to accumulation; A and B increase exposure risk.
Question 2
During a complex medication review, a patient on warfarin and amiodarone is found to have a significantly elevated INR.
Amiodarone inhibits CYP2C9. Which pharmacodynamic and pharmacokinetic interaction best explains the observed effect?
A. Competitive antagonism at the vitamin K epoxide reductase site
B. Induction of CYP2C9 leading to increased warfarin clearance
C. Inhibition of CYP2C9 decreasing S-warfarin metabolism and potentiating anticoagulation
D. Displacement of warfarin from albumin with no change in free fraction over time
Correct Answer: C
Rationale:
Amiodarone is a potent CYP2C9 inhibitor, reducing clearance of the more potent S-enantiomer of warfarin and increasing anticoagulant effect.
Displacement is transient; induction would lower INR.
,NUR 635 FINAL EXAM 1 GCU 2026/2027 | ADVANCED PHARMACOLOGY Page 3
Question 3
A critically ill patient receives a loading dose of vancomycin calculated for a target trough of 15-20 mcg/mL. Subsequent troughs
remain subtherapeutic despite dose increases. The clinical pharmacist notes the patient has augmented renal clearance. Which
pharmacokinetic parameter is most responsible?
A. Decreased volume of distribution secondary to fluid shifts
B. Increased glomerular filtration rate accelerating drug elimination
C. Reduced bioavailability due to gut edema
D. Protein binding changes increasing free fraction
Correct Answer: B
Rationale:
Augmented renal clearance in critical illness elevates GFR, increasing clearance of renally eliminated drugs like vancomycin and producing
subtherapeutic levels. Vd changes affect peak more than trough steady-state.
Question 4
A patient with hepatic cirrhosis Child-Pugh C requires therapy with a high-extraction-ratio drug that undergoes extensive first-pass
metabolism. Which dosing consideration is most critical?
A. Oral bioavailability will be markedly increased; reduce oral dose substantially
B. Intravenous clearance remains unchanged; no dose adjustment needed
C. Protein binding increases; free fraction decreases
D. Volume of distribution decreases due to ascites
Correct Answer: A
Rationale:
In cirrhosis, reduced hepatic blood flow and enzyme activity decrease first-pass extraction, raising oral bioavailability of high-extraction drugs. IV
clearance is also reduced but the oral effect is more dramatic.
Question 5
When comparing two beta-blockers, Drug A has a half-life of 4 hours and Drug B has a half-life of 12 hours. Both are administered
to steady state. Which statement regarding time to steady state is correct?
A. Drug A reaches steady state faster because of its shorter half-life
B. Both reach steady state at the same time because dosing frequency dominates
C. Drug B reaches steady state faster due to longer residence time
D. Steady-state time is independent of half-life and depends only on clearance
Correct Answer: A
Rationale:
Time to steady state is determined primarily by half-life (approximately 4-5 half-lives). Shorter half-life drugs accumulate and reach steady state
more rapidly.
Question 6
A new oral agent exhibits nonlinear pharmacokinetics above 200 mg due to saturation of first-pass metabolism. At a dose of 400
mg, the AUC is four times greater than expected from dose proportionality. Which clinical implication is most important?
A. Dose increases above the nonlinear threshold produce disproportionate rises in exposure
B. Clearance increases with dose, reducing accumulation risk
C. Bioavailability decreases at higher doses
D. Protein binding becomes saturated, increasing free fraction linearly
Correct Answer: A
Rationale:
Saturable first-pass metabolism causes bioavailability to rise with dose, producing greater-than-proportional AUC increases and higher risk of
toxicity with dose escalation.
, NUR 635 FINAL EXAM 1 GCU 2026/2027 | ADVANCED PHARMACOLOGY Page 4
Question 7
In a patient receiving continuous renal replacement therapy (CRRT), a drug with low protein binding, small molecular weight, and
high volume of distribution is ordered. Which property most limits extracorporeal removal?
A. High volume of distribution indicating extensive tissue binding
B. Low protein binding facilitating filtration
C. Small molecular weight allowing free passage through the membrane
D. High water solubility enhancing dialysate clearance
Correct Answer: A
Rationale:
High Vd means most drug is outside plasma and unavailable for extracorporeal removal. Low protein binding and small size favor removal, but
tissue distribution dominates.
Question 8
A drug is known to be a P-glycoprotein substrate. Co-administration of a strong P-gp inhibitor is planned. Which effect on the
substrate drug is most likely?
A. Decreased absorption and reduced systemic exposure
B. Increased absorption and elevated systemic concentrations
C. Accelerated biliary excretion lowering AUC
D. Induction of renal tubular secretion
Correct Answer: B
Rationale:
P-gp inhibitors reduce efflux of substrate drugs at the intestinal epithelium, increasing absorption and systemic exposure. This is a classic
pharmacokinetic interaction.
Question 9
Two patients receive identical mg/kg doses of a drug. Patient A has a measured clearance twice that of Patient B. Assuming linear
kinetics and same dosing interval, how does steady-state average concentration compare?
A. Patient A will have approximately half the Css of Patient B
B. Both patients will have identical Css because dose is weight-based
C. Patient A will have higher Css due to faster distribution
D. Css is independent of clearance and depends only on half-life
Correct Answer: A
Rationale:
Css,avg = (F x Dose / ) / CL. Higher clearance produces proportionally lower steady-state concentration when dose and interval are fixed.
Question 10
A clinician is selecting an antibiotic for a patient with severe sepsis. The drug exhibits time-dependent killing and a short
post-antibiotic effect. Which dosing strategy optimizes efficacy?
A. High-dose extended-interval administration to maximize peak/MIC
B. Frequent dosing or continuous infusion to maximize time above MIC
C. Once-daily dosing regardless of half-life
D. Loading dose only without maintenance
Correct Answer: B
Rationale:
Time-dependent killers (e.g., beta-lactams) require prolonged T>MIC. Frequent or continuous regimens achieve this better than high peak
strategies used for concentration-dependent agents.
OBJECTIVE ASSESSMENT - EXAM
NUR 635 FINAL EXAM 1 GCU 2026/2027 LATEST
VERSION WITH 130+ ACTUAL EXAM QUESTIONS AND
100% CORRECT ANSWERS GRADED A+ / NUR 635
ADVANCED PHARMACOLOGY ACTUAL FINAL EXAM
2026/2027 (BRAND NEW!!) 2026/2027
A+ Verified Edition: 2026/2027 Passing Score: 80%
Graduate-Level Advanced Pharmacology | Analysis & Evaluation
COVER PAGE - 1
,NUR 635 FINAL EXAM 1 GCU 2026/2027 | ADVANCED PHARMACOLOGY Page 2
SECTIONS COVERED
1. Section 1: Pharmacokinetics, Pharmacodynamics & Principles of Drug Action (22 questions)
2. Section 2: Autonomic Nervous System & Cardiovascular Pharmacology (22 questions)
3. Section 3: Central Nervous System Pharmacology (22 questions)
4. Section 4: Antimicrobial & Anti-Infective Pharmacotherapy (22 questions)
5. Section 5: Endocrine, Respiratory & Gastrointestinal Pharmacology (21 questions)
6. Section 6: Special Populations, Adverse Effects & Clinical Decision-Making (21 questions)
This examination assesses advanced knowledge of pharmacology principles, drug classes, therapeutic applications, adverse-effect
profiles, and clinical decision-making at the graduate level. Each question is worth 1 mark. Passing score: 80%.
Section 1: Pharmacokinetics, Pharmacodynamics & Principles of Drug Action
Question 1
A 68-year-old patient with chronic kidney disease stage 4 is prescribed a new renally cleared antibiotic. The nurse practitioner
reviews the pharmacokinetic profile and notes the drug has a high volume of distribution and is primarily eliminated unchanged in
urine. Which adjustment is most appropriate to maintain therapeutic levels while minimizing toxicity?
A. Increase the dose and extend the dosing interval
B. Maintain the standard dose and shorten the dosing interval
C. Reduce the dose and maintain the standard dosing interval
D. Reduce the dose and extend the dosing interval
Correct Answer: D
Rationale:
For renally cleared drugs with high Vd in CKD, both dose reduction and interval extension are often needed to account for reduced clearance
while respecting distribution. Option C alone may still lead to accumulation; A and B increase exposure risk.
Question 2
During a complex medication review, a patient on warfarin and amiodarone is found to have a significantly elevated INR.
Amiodarone inhibits CYP2C9. Which pharmacodynamic and pharmacokinetic interaction best explains the observed effect?
A. Competitive antagonism at the vitamin K epoxide reductase site
B. Induction of CYP2C9 leading to increased warfarin clearance
C. Inhibition of CYP2C9 decreasing S-warfarin metabolism and potentiating anticoagulation
D. Displacement of warfarin from albumin with no change in free fraction over time
Correct Answer: C
Rationale:
Amiodarone is a potent CYP2C9 inhibitor, reducing clearance of the more potent S-enantiomer of warfarin and increasing anticoagulant effect.
Displacement is transient; induction would lower INR.
,NUR 635 FINAL EXAM 1 GCU 2026/2027 | ADVANCED PHARMACOLOGY Page 3
Question 3
A critically ill patient receives a loading dose of vancomycin calculated for a target trough of 15-20 mcg/mL. Subsequent troughs
remain subtherapeutic despite dose increases. The clinical pharmacist notes the patient has augmented renal clearance. Which
pharmacokinetic parameter is most responsible?
A. Decreased volume of distribution secondary to fluid shifts
B. Increased glomerular filtration rate accelerating drug elimination
C. Reduced bioavailability due to gut edema
D. Protein binding changes increasing free fraction
Correct Answer: B
Rationale:
Augmented renal clearance in critical illness elevates GFR, increasing clearance of renally eliminated drugs like vancomycin and producing
subtherapeutic levels. Vd changes affect peak more than trough steady-state.
Question 4
A patient with hepatic cirrhosis Child-Pugh C requires therapy with a high-extraction-ratio drug that undergoes extensive first-pass
metabolism. Which dosing consideration is most critical?
A. Oral bioavailability will be markedly increased; reduce oral dose substantially
B. Intravenous clearance remains unchanged; no dose adjustment needed
C. Protein binding increases; free fraction decreases
D. Volume of distribution decreases due to ascites
Correct Answer: A
Rationale:
In cirrhosis, reduced hepatic blood flow and enzyme activity decrease first-pass extraction, raising oral bioavailability of high-extraction drugs. IV
clearance is also reduced but the oral effect is more dramatic.
Question 5
When comparing two beta-blockers, Drug A has a half-life of 4 hours and Drug B has a half-life of 12 hours. Both are administered
to steady state. Which statement regarding time to steady state is correct?
A. Drug A reaches steady state faster because of its shorter half-life
B. Both reach steady state at the same time because dosing frequency dominates
C. Drug B reaches steady state faster due to longer residence time
D. Steady-state time is independent of half-life and depends only on clearance
Correct Answer: A
Rationale:
Time to steady state is determined primarily by half-life (approximately 4-5 half-lives). Shorter half-life drugs accumulate and reach steady state
more rapidly.
Question 6
A new oral agent exhibits nonlinear pharmacokinetics above 200 mg due to saturation of first-pass metabolism. At a dose of 400
mg, the AUC is four times greater than expected from dose proportionality. Which clinical implication is most important?
A. Dose increases above the nonlinear threshold produce disproportionate rises in exposure
B. Clearance increases with dose, reducing accumulation risk
C. Bioavailability decreases at higher doses
D. Protein binding becomes saturated, increasing free fraction linearly
Correct Answer: A
Rationale:
Saturable first-pass metabolism causes bioavailability to rise with dose, producing greater-than-proportional AUC increases and higher risk of
toxicity with dose escalation.
, NUR 635 FINAL EXAM 1 GCU 2026/2027 | ADVANCED PHARMACOLOGY Page 4
Question 7
In a patient receiving continuous renal replacement therapy (CRRT), a drug with low protein binding, small molecular weight, and
high volume of distribution is ordered. Which property most limits extracorporeal removal?
A. High volume of distribution indicating extensive tissue binding
B. Low protein binding facilitating filtration
C. Small molecular weight allowing free passage through the membrane
D. High water solubility enhancing dialysate clearance
Correct Answer: A
Rationale:
High Vd means most drug is outside plasma and unavailable for extracorporeal removal. Low protein binding and small size favor removal, but
tissue distribution dominates.
Question 8
A drug is known to be a P-glycoprotein substrate. Co-administration of a strong P-gp inhibitor is planned. Which effect on the
substrate drug is most likely?
A. Decreased absorption and reduced systemic exposure
B. Increased absorption and elevated systemic concentrations
C. Accelerated biliary excretion lowering AUC
D. Induction of renal tubular secretion
Correct Answer: B
Rationale:
P-gp inhibitors reduce efflux of substrate drugs at the intestinal epithelium, increasing absorption and systemic exposure. This is a classic
pharmacokinetic interaction.
Question 9
Two patients receive identical mg/kg doses of a drug. Patient A has a measured clearance twice that of Patient B. Assuming linear
kinetics and same dosing interval, how does steady-state average concentration compare?
A. Patient A will have approximately half the Css of Patient B
B. Both patients will have identical Css because dose is weight-based
C. Patient A will have higher Css due to faster distribution
D. Css is independent of clearance and depends only on half-life
Correct Answer: A
Rationale:
Css,avg = (F x Dose / ) / CL. Higher clearance produces proportionally lower steady-state concentration when dose and interval are fixed.
Question 10
A clinician is selecting an antibiotic for a patient with severe sepsis. The drug exhibits time-dependent killing and a short
post-antibiotic effect. Which dosing strategy optimizes efficacy?
A. High-dose extended-interval administration to maximize peak/MIC
B. Frequent dosing or continuous infusion to maximize time above MIC
C. Once-daily dosing regardless of half-life
D. Loading dose only without maintenance
Correct Answer: B
Rationale:
Time-dependent killers (e.g., beta-lactams) require prolonged T>MIC. Frequent or continuous regimens achieve this better than high peak
strategies used for concentration-dependent agents.
